-transparent.png){kind=logo}
During previous therapeutic trials with interferon, decreased levels of peripheral platelet counts have been observed. Taking advantage of this effect, we investigated the efficacy of recombinant interferon (rec-IFN) in the treatment of thrombocytosis in myeloproliferative diseases. A total of 15 patients with polycythemia vera, essential thrombocytosis, or chronic myeloid leukemia received rec-IFN-alfa at initial doses of 25-70 x 10(6) units/week; maintenance therapy following week 8 of treatment consisted of 20-35 x 10(6) units/week rec-IFN. Observation periods ranged from 24 to 48 weeks. Significant reductions in the number of platelets were noted in all cases; 12/15 patients achieved platelet counts below 440 x 10(9)/l and maintained those normal values for at least 4 weeks. The number of bone marrow megakaryocytes, which had been increased prior to treatment, diminished during rec-IFN therapy, while the previously shortened platelet half-life further decreased with rec-IFN treatment. During rec-IFN-induced remission, the plasma levels of platelet factors, the activity of natural killer cells, and platelet aggregation showed changes between slight improvement and normal values. Severe side effects were only observed with the highest rec-IFN doses; dosage adjustments were effective in improving or eliminating all treatment-related symptoms. Rec-IFN may prove to be a valuable therapeutic alternative to cytostatic treatment of thrombocytosis in myeloproliferative disorders.
H Ludwig, and
W Linkesch, and
H Gisslinger, and
E Fritz, and
H Sinzinger, and
T Radaszkiewicz, and
A Chott, and
R Flener, and
M Micksche
January 1991,
European journal of cancer (Oxford, England : 1990),
H Ludwig, and
W Linkesch, and
H Gisslinger, and
E Fritz, and
H Sinzinger, and
T Radaszkiewicz, and
A Chott, and
R Flener, and
M Micksche
January 1989,
Blut,
H Ludwig, and
W Linkesch, and
H Gisslinger, and
E Fritz, and
H Sinzinger, and
T Radaszkiewicz, and
A Chott, and
R Flener, and
M Micksche
August 2002,
The British journal of dermatology,
H Ludwig, and
W Linkesch, and
H Gisslinger, and
E Fritz, and
H Sinzinger, and
T Radaszkiewicz, and
A Chott, and
R Flener, and
M Micksche
May 1989,
The American journal of medicine,
H Ludwig, and
W Linkesch, and
H Gisslinger, and
E Fritz, and
H Sinzinger, and
T Radaszkiewicz, and
A Chott, and
R Flener, and
M Micksche
November 1993,
Medicina clinica,
H Ludwig, and
W Linkesch, and
H Gisslinger, and
E Fritz, and
H Sinzinger, and
T Radaszkiewicz, and
A Chott, and
R Flener, and
M Micksche
January 1991,
European journal of cancer (Oxford, England : 1990),
H Ludwig, and
W Linkesch, and
H Gisslinger, and
E Fritz, and
H Sinzinger, and
T Radaszkiewicz, and
A Chott, and
R Flener, and
M Micksche
January 1982,
British journal of haematology,
H Ludwig, and
W Linkesch, and
H Gisslinger, and
E Fritz, and
H Sinzinger, and
T Radaszkiewicz, and
A Chott, and
R Flener, and
M Micksche
June 1989,
British journal of haematology,
H Ludwig, and
W Linkesch, and
H Gisslinger, and
E Fritz, and
H Sinzinger, and
T Radaszkiewicz, and
A Chott, and
R Flener, and
M Micksche
June 1985,
British journal of haematology,
H Ludwig, and
W Linkesch, and
H Gisslinger, and
E Fritz, and
H Sinzinger, and
T Radaszkiewicz, and
A Chott, and
R Flener, and
M Micksche
January 1995,
Acta haematologica Polonica,
